Videos

Andrew Cowan, MD, discusses the complexities of relapsed multiple myeloma, distinguishing between biochemical and clinical progression, analyzing survival data, and raising questions about optimal treatment strategies.

An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.

A retrospective analysis of arterial occlusive events in the PACE trial, shedding light on risk factors and management strategies for ponatinib treatment in CML patients.

An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.

Closing out their program on renal cell carcinoma management, key opinion leaders share closing thoughts on emerging therapies and how the field is evolving.

Daniel Ahn, DO, discusses the evolution of biomarker testing in metastatic colorectal cancer, highlighting the shift from understanding only the prognostic implications of genetic alterations to recognizing their predictive role in targeted therapies, and emphasizes the potential of circulating tumor DNA for rapid diagnosis and assessing treatment response.

Tanios Bekaii-Saab, MD, and colleagues address updates in metastatic colorectal cancer treatment, highlighting its prevalence in the U.S., the concerning rise in younger patients, and the ongoing uncertainty regarding the causes of this trend, with potential factors like environment and microbiome under investigation.

The expert panel discusses factors that influence referral to transplant as well as selecting maintenance and consolidation therapies for patients with multiple myeloma.

Key opinion leaders in the field of multiple myeloma review data looking at patient outcomes in the GRIFFIN and MASTER trials based on cytogenetic abnormalities.

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 68-year-old man with transplant-ineligible newly diagnosed multiple myeloma to the expert panel for discussion.

Natasha Garg, DO, MS, and Neel Talwar, MD, explain the resources they utilize at City of Hope for treating patients with high-risk newly diagnosed multiple myeloma.

Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.

Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.

Catherine Lee, MD, MS, details her approaches to tapering steroids in a refractory patient with chronic graft-versus-host disease and the efficacy of different treatments based on organ involvement.

Nelson Chao, MD, MBA, presents the clinical scenario of a 52-year-old woman with chronic graft-versus-host disease for discussion.

Centering discussion on sarcomatoid and rhabdoid non-clear cell renal cell carcinoma, panelists consider frontline IO-based regimens and their value in this setting.

A brief discussion centered on optimal treatment strategies for patients with chromophobe or papillary kidney cancers.

Drs Jain and Shah discuss the future of patient care in metastatic bladder cancer, while Mr. and Mrs. Ehas share advice for patients with bladder cancer, advice for caregivers and closing thoughts on their overall journey.

Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.

Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.

A detailed overview of therapeutic options for patients undergoing treatment for newly diagnosed multiple myeloma.

A panel of experts on multiple myeloma discuss the decision to refer patients with newly diagnosed multiple myeloma for transplant.

Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.

A panel of experts from City of Hope and satellite clinics review the available frontline therapy options for patients with transplant-eligible newly diagnosed multiple myeloma.

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 61-year-old woman with transplant-eligible newly diagnosed multiple myeloma to the panel for discussion.

Luspatercept, which is now FDA approved for myelodysplastic syndromes, may help patients achieve transfusion independence.

Experts discuss the second-line treatment options for chronic graft-vs-host disease when steroids fail, including ruxolitinib.

Erin Kopp, NP, emphasizes the importance of identifying patient response to steroids, establishing steroid dependence, and using a systematic tapering regimen for effective management of chronic graft-vs-host disease.

Key opinion leaders in the field of renal cell carcinoma management reflect on recent data with IO/TKI combination therapy in patients with non-clear cell disease.

Switching its focus to non-clear cell RCC, the panel reviews data presented at ASCO 2023 on KEYNOTE-B61, combining lenvatinib + pembrolizumab in this setting.